Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB CAR-NK182 in Advanced Gastric and Pancreatic Cancer
NCT06464965Phase 1Completed
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CB CAR-NK182 in gastric cancer (GC) and pancreatic adenocarcinoma (PDAC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Maximum Tolerated Dose at 1 month and Dose-Limiting Toxicity at 1 month. Started Jul 2024; status: completed.
02
Drugs
CB CAR-NK182
03
Conditions
gastric cancer (GC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06464965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464965.